Journal article
Steady-State pharmacokinetics and tolerability of Indinavir-Lopinavir/R Combination therapy in Antiretroviral-experienced patients
Therapeutic Drug Monitoring, Vol.27(6), pp.779-781
2005
Abstract
Six HIV-positive antiretroviral experienced patients initiating therapy with a regimen including lopinavir/ritonavir (400/100 mg twice per day) and indinavir (800 mg twice per day) underwent steady-state pharmacokinetic analysis. The AUC0-12h of indinavir when combined with lopinavir/ritonavir was comparable with previously published data on indinavir/ritonavir 800/100 mg twice per day in HIV-infected individuals. However, lopinavir AUC0-12h, Cmax, and C12h were lower than previously reported in the absence of indinavir. The regimen was well tolerated, although 2 patients developed grade 3 hypertriglyceridemia. No patient discontinued the regimen because of indinavir-related urologic or retinoid-type adverse effects. Further study of the regimen with larger cohorts of patients is necessary.
Details
- Title
- Steady-State pharmacokinetics and tolerability of Indinavir-Lopinavir/R Combination therapy in Antiretroviral-experienced patients
- Authors/Creators
- T. Antoniou (Author/Creator)A.L. Tseng (Author/Creator)R.P.G. van Heeswijk (Author/Creator)S.E. Walker (Author/Creator)P. Giquere (Author/Creator)E.J. Phillips (Author/Creator)
- Publication Details
- Therapeutic Drug Monitoring, Vol.27(6), pp.779-781
- Publisher
- Lippincott Williams & Wilkins
- Identifiers
- 991005546354307891
- Copyright
- © 2005 Lippincott Williams & Wilkins, Inc.
- Murdoch Affiliation
- Murdoch University
- Language
- English
- Resource Type
- Journal article
Metrics
43 Record Views